Acceptance of Prognostic Fine Needle Aspiration Biopsy for Uveal Melanoma.
PURPOSE: To report patient acceptance of prognostic fine needle aspiration biopsy (FNAB) for uveal melanoma. METHODS: Retrospective analysis of data derived from 200 consecutive patients with uveal melanoma (11/2013 to 7/2016). Patients underwent prognostic FNAB in addition to routine standard-of-ca...
| Publicado en: | Insight: The Journal of the American Society of Ophthalmic Registered Nurses Vol. 42; no. 3; pp. 12 - 15 |
|---|---|
| Autores principales: | , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
American Society of Ophthalmic Registered Nurses
Summer2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124022973&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 124022973 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1060135X DOH jtl: Insight: The Journal of the American Society of Ophthalmic Registered Nurses issn: 1060135X maglogo: N pubinfo: dt: Summer2017 vid: 42 iid: 3 pid: 28614 pub: American Society of Ophthalmic Registered Nurses place: San Francisco, California artinfo: ui: 124022973 124022973 124022973 124022973 ppf: 12 ppct: 3 formats: fmt: @attributes: type: P tig: atl: Acceptance of Prognostic Fine Needle Aspiration Biopsy for Uveal Melanoma. aug: au: Davanzo, Jacquelyn Bellerive, Claudine Petrich, Dina Singh, Arun D. affil: Cole Eye Institute, Cleveland Clinic, Cleveland, OH sug: subj: Uveal Neoplasms Diagnosis Melanoma Diagnosis Melanoma Prognosis Diagnosis, Laboratory Methods Biopsy, Needle Methods Decision Making, Patient Human Retrospective Design Descriptive Statistics Gene Expression Profiling Melanoma Therapy ab: PURPOSE: To report patient acceptance of prognostic fine needle aspiration biopsy (FNAB) for uveal melanoma. METHODS: Retrospective analysis of data derived from 200 consecutive patients with uveal melanoma (11/2013 to 7/2016). Patients underwent prognostic FNAB in addition to routine standard-of-care treatment. Prognostication was performed using commercially available Multiplex Ligation-dependent Probe Amplification (MLPA, Impact Genetics; Toronto, Canada) or Gene Expression Profiling (GEP, Castle Biosciences; Dallas, TX). RESULTS: Tumors were located in the iris (15, 7.5%), ciliary body (30, 15%), or choroid (155, 72.5%) (see Table 1). The majority of patients underwent plaque radiation therapy (147, 73.5%) or enucleation (41, 20.5%). The remaining were treated by iridectomy (9, 4.5%), transpupillary thermotherapy (2, 1%), or proton beam radiation (1, 0.5%). FNAB was offered to 145 patients (72.5%). Seven patients (5%) refused prognostic FNAB. Of the 138 patients who underwent FNAB, 76 were classified as being at low risk for metastases; 57 (41%), at high risk; and in 5 patients (4%) there was technical failure to process the sample. CONCLUSIONS: The vast majority of patients (95%) undergoing treatment for uveal melanoma accept to undergo prognostic FNAB when offered. The overall technical failure rate is low (4%) but should be mentioned during patient counseling. Only about 30% of cases (those at high risk for metastases) would be eligible to enter any available adjuvant therapy trial. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|